On September 11, EVEREST MED fell 5.39% in regular trading to HKD 27.06, with turnover of approximately HKD 53.33 million, marking the fourth consecutive trading day of decline. The sell-off was driven by mounting market concerns over the company's strategic cooperation framework agreement with Haisen Biopharmaceutical, compounded by ongoing profit-taking following the Xinbito approval catalyst.

On September 9, the company's wholly-owned subsidiary signed a strategic cooperation framework agreement with Haisen covering product supply, distribution, manufacturing, and commercialization in China, with procurement caps escalating to a maximum of RMB 3.076 billion by 2028. Additionally, existing commercialization service fees payable by Haisen to the company are set at RMB 560 million, RMB 616 million, and RMB 677 million for 2026-2028 respectively. As Haisen is a connected party, investors have raised significant concerns regarding transaction pricing fairness, accounts receivable risk exposure, and minority shareholder protections — issues previously flagged during the company's earlier attempt to acquire Haisen equity.

Meanwhile, the positive catalyst from Xinbito's NMPA approval on September 3 — the first and only innovative therapy approved for adult PSVT acute episodes in over 30 years — has been largely priced in since the September 8 rally of over 5%, with sustained selling pressure persisting across subsequent sessions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)